READOUT CAPITAL, LP
READOUT CAPITAL, LP is a Pre-seed, Seed and early-stage fund in the US investing in AI, biotechnology and life-sciences.
- Stages
- Pre-seed, Seed, early-stage
- Sectors
- AI, biotechnology, life-sciences
- Invests in
- US-wide
- Actively investing
- Yes
- Founded
- 2023
- Assets under management
- $25.86M
Check size not disclosed
Thesis
Readout Capital, LP is an investment firm with a primary focus on the biotechnology and life sciences sectors. Their investment thesis centers on companies that utilize artificial intelligence to enhance the speed and effectiveness of clinical trial data analysis and insight generation. The firm manages private funds with a total gross asset value of $25.86 million, including a venture capital fund valued at $17.067 million. They operate as an Exempt Reporting Adviser (ERA) with the SEC. Readout Capital invests in early-stage companies, as demonstrated by their participation in a pre-seed funding round for Readout AI. Smith's background includes leading biotech investing, while Dahlman's expertise as a professor and inventor has led to licensing his inventions to numerous companies. The firm's LEI was issued on August 11, 2023, suggesting a recent establishment. Their headquarters are in Washington, D.C.
Common questions
Does READOUT CAPITAL, LP invest at the Pre-seed stage?
Yes. READOUT CAPITAL, LP lists Pre-seed, Seed and early-stage among the stages it invests in.
Where does READOUT CAPITAL, LP invest?
READOUT CAPITAL, LP invests in the US.